About Technology Products Partners Careers News Contact About us Enara Bio™ (formerly known as Ervaxx) is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. We were founded as Ervaxx Ltd in late 2016 with an initial focus on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-related DNA sequences. Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness. We are exploring the hidden depths of cancer and T-cell biology to discover and characterize unconventional immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, which arise from the altered cellular processes in cancer cells. Enara Bio is backed by leading life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with a number of world class academic institutions including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive our differentiated science. WATCH THE FILM Management Team Rachel Abbott Head of TCR Pipeline and Dark Antigen Research Mark Creighton-Gutteridge Vice President, Head of Research Matthew Davies Head of Bioinformatics Jonathon Dines Finance Director Joseph Dukes Vice President, Translational Science Andrew Fadden Vice President, Corporate Development Charlotte Howard Executive Administrator Duncan Howie Associate Director, Immunology Martin Kreutz Head of Cell Therapy Process Development Fabio Marino Associate Director, Immunoproteomics Peter Mason Head of Product Platform Science and Technology Kevin Pojasek President and Chief Executive Officer Erik Rutjens Vice President, Cell Therapy Operations Hayden Selvadurai Associate Director, Corporate Development Soreya Senior Director of HR, People and Culture Nicola Ternette Director, Immunopeptidomics Bethany Turner Associate Director, Corporate Operations David Watson Chief Operating Officer Ron Wolchinsky Associate Director, Molecular Immunology Board of Directors Houman Ashrafian Chairperson and co-founder Josh Resnick Director Mike Dybbs Director Robert Ang Non-executive Director Veronique Birault Board Observer Kevin Pojasek President and Chief Executive Officer Scientific Advisory Board Adrian Hill, MB BCh DPhil University of Oxford, Oxford, UK. Find out more Sadik Kassim PhD CTO, Vor Biopharma Find out more George Kassiotis, PhD Co-founder. Francis Crick Institute, London, UK. Find out more Mike Quigley, PhD Senior Vice President, Gilead Find out more Drew Pardoll, MD PhD Co-founder. Johns Hopkins University, Baltimore, USA. Find out more Andrew Sewell, PhD Cardiff University, Cardiff, UK. Find out more Nicola Ternette, PhD University of Oxford, Oxford, UK. Find out more Eliezer Van Allen, MD PhD Dana-Farber Cancer Institute, Boston, USA. Find out more Enara Bio About Technology Products Partners Careers News Contact Legal Website Terms Privacy Policy © 2021 Enara Bio | All rights reserved Enara Bio, Dark Antigen and EDAPT are trademarks of Enara Bio Limited Site by Ether